Abstract:Zhuoyue Wang, 1, 2, &ast Hui Li, 3, 4, &ast Yimin Kang, 1, &ast Yanlong Liu, 5, &ast Ligang Shan, 6 Fan Wang 2, 4 1 Psychosomatic Medicine Research Division, Inner Mongolia Medical University, Huhhot, People's Republic of China; 2 Beijing Hui-Long-Guan Hospital, Peking University, Beijing, People's Republic of China; 3 Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, People's Republic of China; 4 Xinjiang Key Laboratory of Neurological Disorder Research, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China; 5 School of Mental Health, Wenzhou Medical University, Wenzhou, People's Republic of China; 6 Department of Anesthesiology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fan Wang, Beijing Hui-Long-Guan Hospital, Peking University, Beijing, 100096, People's Republic of China, Tel +86 10 83024429, Fax +86 10 62716285, Email Purpose: Selective serotonin reuptake inhibitors (SSRIs) are the preferred treatments for depression. The most common adverse drug reactions are symptoms involving the digestive system, leading to low compliance in patients with depression. Therefore, it is important to assess the safety of SSRIs with respect to the digestive system. Several meta-analyses have compared the risks of digestive side effects of SSRIs and other antidepressants. We aimed to compare the risks of various SSRIs (fluoxetine, escitalopram, citalopram, paroxetine, and sertraline) for adverse reactions of the digestive system. Methods: Systematic searches returned 30 randomized controlled trials (n = 5004) of five antidepressants and placebos. Results: Fluoxetine had the lowest probability of digestive side effects, ranking fifth at 0.548. Sertraline had the highest probability of digestive side effects, with a probability of 0.611. For gastrointestinal tolerability, escitalopram was better than paroxetine (odds ratio [OR] =0.62, 95% confidence interval [CI] 0.43– 0.87) and sertraline (OR=0.56, 95% CI 0.32– 0.99). Conclusion: Fluoxetine exhibited distinct advantages compared to other SSRIs, while sertraline had the greatest likelihood of digestive system side effects. These findings will help doctors understand the relative advantages of various antidepressants. Keywords: depression, selective serotonin reuptake inhibitors, digestive system side effects, network meta-analysis Depression is the most common psychiatric disorder, and SSRIs are first-line drugs for its treatment. 1,2 Among SSRIs, fluoxetine, escitalopram, citalopram, paroxetine, and sertraline are the most prescribed drugs. 3 SSRIs act by inhibiting the 5-hydroxytryptamine (5-HT) transporter (5-HTT) on the axonal terminals of serotonergic neurons in the raphe nuclei, which terminates serotonin signaling through rapid presynaptic reuptake. 4 Under the action of SSRIs, 5-HT reuptake is inhibited; therefore, the levels of 5-HT in the neurosynaptic junction are increased, leading to the relief of depression symptoms. 5 SSRIs are usually taken orally, 6 but orally administered drugs often cause gastrointestinal side effects, which may lead to poor patient compliance. Some adverse drug reactions can occur during SSRI treatment, the most common of which are symptoms concerning the digestive system and abdomen, such as nausea and diarrhea, possibly owing to the increase in the usability of 5-HT in the gastrointestinal system. Digestive side effects appear early in the treatment process, which is extremely common during the critical first few weeks of treatment and poses a risk of patient noncompliance. 7,8 Some studies have shown that fluoxetine can cause diarrhea and nausea. 9,10 However, studies have also shown that fluoxetine can be used to treat constipation. 11 Nausea occurred in 42.5% of the escitalopram-treated patients. 12 Acute treatment with citalopram also temporarily reduced gastric basal tone and gastric regulation, leading to nausea. 13,14 In addition to causing nausea, paroxetine causes constipation by delaying upper gastrointestinal transit. 15,16 However, sertraline was related to a significantly lower frequency of constipation and a higher frequency of nausea and diarrhea. 13,17 Diarrhea and nausea were the most common adverse associated with vilazodone and venlafaxine. 18–20 Although several meta-analyses have c -Abstract Truncated-

Eye Disorders Associated with Selective Serotonin Reuptake Inhibitors: a Real-World Disproportionality Analysis of FDA Adverse Event Reporting System

Central Serous Chorioretinopathy Secondary to Drugs: a Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).

Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System

(100) Urinary and Gynecologic Adverse Events Associated with Ssri Use

Association of Selective Serotonin Reuptake Inhibitor Use and Acute Angle-Closure Glaucoma

Analysis of prescriptions of three selective serotonin reuptake inhibitors from a perspective of metabolic interactions

Mydriasis caused by ESCITALOPRAM: A case report

Possible Sertraline-Induced Extrapyramidal Adverse Effects in an Adolescent.

Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database

Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review

Drug–Drug Interactions of Selective Serotonin Reuptake Inhibitors: A Pharmacovigilance Study on Real-World Evidence from the EudraVigilance Database

Effects of selective serotonin reuptake inhibitors on intraocular pressure and anterior segment parameters in open angle eyes

Characteristics of eye disorders induced by atypical antipsychotics: a real-world study from 2016 to 2022 based on Food and Drug Administration Adverse Event Reporting System

Risk of stress cardiomyopathy associated with selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors: a real-world pharmacovigilance analysis

Patterns of SSRI Exposures Reported to the U.S. Poison Centers

Dry Eye Related to Commonly Used New Antidepressants

Eye disorders associated with newer antiepileptic drugs: A real-world disproportionality analysis of FDA adverse event reporting system

Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis

Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database

ADR Induced by Selective Serotonin Reuptake Inhibitors:Literature Analysis

SSRI use during acute COVID-19 and risk of long COVID among patients with depression